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Abstract Background and Objective: The management of diabetic neuropathy is still
a challenge for physicians. The aim of this study was to assess the efficacy of
a new combination of alpha lipoic acid and superoxide dismutase for the
treatment of diabetic neuropathy.
Methods: The setting of this study was ambulatory (outpatient) care. A pro-
spective, non-randomized, open-label study was conducted in 50 patients
with diabetes mellitus and with a deficit in both motor and sensory nerve
conduction. Treatment was with a new combination of alpha lipoic acid and
superoxide dismutase (ALA600SOD) for 4 months. Electroneurographic
parameters and perceived pain were assessed at baseline and after treatment.
Results: After 4 months of treatment, patients significantly (p< 0.001) improved
their electroneurographic parameters and their perception of pain. Best im-
provements were observed in sensory nerve conduction.
Conclusion: The combination of two powerful antioxidant agents leads to
improvement in both subjective and objective parameters in patients with
diabetic neuropathy. New profitable directions for investigations are opened
for a non-invasive treatment of diabetic neuropathy in the future.
Introduction
Neuropathy is a microvascular complication
of diabetes mellitus that leads to considerable
morbidity and a decreased quality of life.[1,2] Di-
abetic neuropathy (DN) is a term indicating all
signs and symptoms of peripheral nerve dysfunc-
tion in diabetic patients in whom other causes of
neuropathy have been excluded[3,4] and it is a
major public health problem, affecting approx-
imately 13–26% of diabetic patients.[5-9] Conduction
studies help to identify and localize focal lesions
in a nerve by demonstrating localized slowing down
or conduction block. In fact, electrophysiologi-
cal testing plays an important role in detecting,
characterizing and measuring DN. Nevertheless,
assessing the severity of painful symptoms and
the nerve conduction slowing down is important
not only for diagnosis but also to assess the ben-
efits of treatment.
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The understanding that oxidative stress is a
unifying mechanism for the cellular pathways
that lead to diabetes complications strongly in-
dicates the use of antioxidants in therapies aimed
at the prevention of diabetes and the potential
reversal of its complications.[10,11] The data so far
suggest a number of therapeutic strategies.[9,11,12]
According to a recent review,[13] at least 50 molec-
ular formulations have reached the clinical stage
of development. Although several analgesic ther-
apies are available to alleviate the symptoms of
diabetic neuropathic pain, few options are avail-
able to eliminate the root causes and DN remains
a challenge for physicians.[14]
In animal studies, alpha lipoic acid (ALA) has
been shown to prevent or even reverse hyper-
glycemia-induced nerve dysfunction by reducing
free-radical-mediated oxidative stress.[15] It has also
been demonstrated that ALA improves nerve
blood flow and peripheral nerve fiber conduction
and increases endoneurial glucose uptake and
energy metabolism in experimental diabetic peri-
pheral neuropathy.[16] Two meta-analyses of ran-
domized, placebo-controlled trials using ALA
infusions of 600mg intravenously/orally per day
for 3 weeks in diabetic patients with positive symp-
toms of peripheral neuropathy have been pub-
lished[1,17] and suggest that this treatment produces
clinically significant improvements in neuropathic
symptoms and deficits. When given intravenously,
ALA leads to a significant and clinically relevant
reduction in neuropathic pain. Improvements with
oral administration are less described but strongly
marked after just 2 weeks of treatment.[9] Never-
theless, there are a lack of significant data on the
effects of ALAs on nerve conduction velocity.
Superoxide dismutase (SOD) is an essential,
ubiquitous enzyme that detoxifies highly reactive
O2
- by catalysis into H2O2, which in turn is re-
duced in H2O in the mitochondria by glutathione
peroxidase and catalase.[18] SOD, which has the
important role of neutralizing superoxide radi-
cals, is reduced in diabetic peripheral nerve tissue,
thus compounding any enhancement of free
radical formation.[19-21] Furthermore, SOD has
a key role in inhibiting inflammatory response,
which is closely correlated with attenuation of
hyperalgesia.[22]
Since oxidative stress is enhanced in diabetic
patients with neuropathy,[12] a pharmacologic
strategy aimed at overcoming the deficit of anti-
oxidant agents should provide significant relief
from complications for neuropathic patients. The
ideal treatment should prevent or arrest the pro-
gressive loss of nerve functionality and improve
symptoms with minimal side effects.
A new oral formulation combining ALA and
SOD, two powerful antioxidant agents singly active
in DN, has been proposed as a powerful tool in
the treatment of DN.
The aim of this pilot study was to assess changes
in nerve conduction velocity and symptomatology
in patients with DN treated daily for 4 months with
a combination of ALA and SOD.
Patients and Methods
From May to November 2010, a prospective,
non-randomized, open-label, pivotal study was
conducted.
The study population included patients with
diabetes and with diabetic symmetric sensorimotor
polyneuropathy.[23] Patients were treated orally for
4 months with ALA 600mg and SOD 140 IU/day
(ALA600 SOD, Alfa Wassermann, Bologna,
Italy).
Data on sex, age and type of diagnosis were
collected. Visual analog scale (VAS) was used at
baseline and at the end of the 4-month treatment.
Electroneurography parameters were assessed by
a Dantec (Dantec, Skovlunde, Denmark) keypoint
device to collect the signal and for the recording
of the responses. The subjects were seated in a
comfortable chair and instructed to be as relaxed
as possible. Electroneurography parameters in-
cluded motor nerve (peroneal) conduction and
sensory (sural) nerve conduction.
Differences between baseline and post-treatment
values were recorded for all measured variables.
All patients were notified of the investigational
nature of this study and gave their written in-
formed consent. The study was approved by the
institutional review board in accordance with in-
stitutional guidelines, including the Declaration
of Helsinki. Any adverse event that occurred dur-
ing the study period was recorded.
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Results are reported as descriptive statistics.
Quantitative parameters are reported as mean,
minimum, maximum and standard deviations;
qualitative parameters are reported as absolute
and relative frequencies.
Student’s t-test for paired data andWilcoxon’s
signed-rank test were used. To assess the differ-
ence between sub groups a Mann Whitney-U test
and a Fisher’s exact test were performed.
p-Values were considered statistically significant
if <0.05. Statistical analyses were performed with
SPSS Statistical Package, version 15.0 (IBM,
Armonk, NY, USA).
Results
Fifty patients affected by DN among out-
patients attending the clinic of Unita` Spinale
dell’Ospedale Santa Corona di Pietra Ligure,
Savona, Italy, were prospectively and consec-
utively enrolled. All the subjects had had type
2 diabetes since 1999 and were treated for this
pathology. Twelve patients were discarded due to
lacking data or missing follow-up. In two patients
no efficacy data were available, ten patients were
lost to follow-up due to intercurrent diseases or
noncompliance. The final dropout rate was 24%.
In the final sample there were 38 patients valuable
for the purpose of this study: 17 females and
21 males with a median age of 68.2 years (–7.4),
all with diabetes and with a deficit in nerve veloc-
ity conduction (diabetic symmetric sensorimotor
polyneuropathy).[23]
All measured variables were tested for sex
differences due to sex dimorphism suggested by
clinical observation. In fact, nerve conduction
abnormalities have been previously reported as
more frequent and severe in males, while neuro-
pathic pain and negative sensory symptoms seem
to be more frequent in female patients.[24,25] No
statistically significant differences were observed
between sexes in our patients, thus we report re-
sults for the whole sample.
All the measured characteristics significantly
improved after treatment (p < 0.001, table I). The
nerve conductions, both motor and sensory, in-
creased and perceived pain improved. The rate of
increment of conduction velocity is greater in the
sensory nerve (12.1%) than in the motor nerve
(7.1%). We labelled a good improvement partic-
ularly in sensory nerve conduction; most of the
patients had an increment ‡10%.
Less than 10% of patients retained stable
measurements in each of the three parameters
and worsening of the measured parameters was
not observed in any patient (figure 1).
Fifty patients were used for safety analysis and
no adverse event occurred during the study.
Discussion
DN is a neuropathic disorder that is associated
with diabetes. This condition is thought to result
from diabetic microvascular injury involving small
blood vessels that supply the nerves (vasa nervorum).
After all, DN is a degenerative pathology with a
progressively disabling course, affecting all peri-
pheral nerves: pain fibers, motor neurons, and
autonomic nerves.[26] It can therefore affect all
organs and systems since all are innervated.
Though therapies are available to alleviate the
symptoms of DN, few options are available to
eliminate the root causes. The immense physical,
psychological, and economic costs of DN underline
the need for causally targeted therapies. In fact,
causal treatments aim at slowing down pathology
Table I. Parameters pre- and post-treatment with variation in the whole samplea
Variable Pre-treatment Post-treatment Variation p-Value
VAS (score) 5.5 –0.6 (5–7) 4.5 – 0.6 (4–6) -1.0 –0.4 (-2–0) <0.001
MNC (m/sec) 36.6 –2.9 (30–40) 39.2 – 3.5 (32–45) 2.5 –1.6 (0–7) <0.001
SNC (m/sec) 32.3 –6.2 (22–45) 36.2 – 6.1 (25–48) 3.9 –2.2 (0–12) <0.001
a Data expressed as mean –SD (range).
MNC =motor nerve conduction; SNC = sensory nerve conduction; VAS = visual analog scale.
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progression besides reducing use of analgesics
and improving nerve deficits.[27]
ALA is a powerful antioxidant and several
studies – including the SYDNEY2 trial – have
demonstrated an improvement in neuropathic
symptoms and deficits.[9] Results of a meta-
analysis[28] provided evidence that treatment with
ALA 600mg/day over 5 weeks is safe and signif-
icantly improves both neuropathic symptomatology
and neuropathic deficits to a clinically meaning-
ful degree in diabetic patients with symptomatic
polyneuropathy.
SOD protects nerves from injury in cell culture
and in animal models of DN.[29] Direct activity on
nerve fibers exposed to oxidative stress and in-
direct activity targeting vasa nervorummake SOD
a powerful adjuvant tool in the treatment of DN.
Our diagnostic group aims to detect specific
sensory profiles through clinical examination,
questionnaires dedicated to neuropathic pain and
laboratory tools.
A new oral formulation combining ALA and
SOD was investigated in this prospective pilot
study, through assessment of changes in nerve con-
duction velocity and patients’ symptomatology.
Previous studies reported that one potential
limitation of the standard electrophysiological
techniques is in detecting therapeutic benefit. Our
study stated that the improvement of nerve con-
duction velocity (objective data) matches the im-
provement of perceived pain in diabetic patients
(subjective data). Furthermore, we observed a
greater improvement in the sensory nerve con-
duction than in the motor conduction, which could
suggest a preferential action of the ALA and SOD
formulation that may indicate a future direction of
investigation.
The synergistic action of ALA and SOD im-
proves both nerve conduction velocity and per-
ceived pain, stating few or absent side effects of
this formulation and of the two single components
already confirmed by clinical and postmarketing
surveillance.[17,30] SOD prevents the formation of
free radicals and ALA promotes their removal;
furthermore, the oral formulation (with improved
bioavailability) improves the patient’s quality of
life, removing the burden of infusion therapy. In
addition, this neurotrophic integrator shows clin-
ically relevant results over a brief time period with
homogeneous improvements amongst patients.
We report the present study as a clinical ex-
perience because we chose a per protocol analysis
to maximize the opportunity for the proposed
treatment to show its efficacy and the actual num-
ber of enrolled patients was relatively small as a
prospective study. Further studies (e.g. a phase
III, multicenter trial with a group treated with



























Fig. 1. The percentages of patients that improved, remained stable or worsened in the measured parameters after treatment. MNC =motor
nerve conduction; SNC = sensory nerve conduction; VAS = visual analog scale.
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are warranted to support our results with a greater
sample size and to investigate placebo effects and
longer follow-up for duration of response and
for treatment safety. Furthermore, future research
should quantify the added value of SOD over
ALA.
Conclusion
Our study is the first to show that treatment
with a combination of ALA and SOD leads to an
improvement both in symptomatology and in
electroneurographic parameters in patients af-
fected by DN.
The results suggest a new scenario for the man-
agement of DN, a new non-invasive treatment
with no registered adverse events. This pivotal study
indicates future directions for useful investigation.
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